Entering text into the input field will update the search result below

FDA Ad Com approaches for Sanofi and Lexicon's sotagliflozin

Jan. 15, 2019 8:45 AM ETSanofi (SNY) StockSNY, LXRXBy: Douglas W. House, SA News Editor
  • The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Thursday, January 17, to review and discuss Sanofi's (NASDAQ:SNY) marketing application seeking approval for orally administered Zynquista (sotagliflozin) as an adjunct to insulin to improve glycemic control in adults with type 1 diabetes.
  • Shares are up 1% premarket while co-development partner Lexicon Pharmaceuticals (NASDAQ:LXRX) is up 2%.
  • FDA briefing doc
  • Errata to FDA briefing doc
  • Sanofi briefing doc 

Recommended For You

More Trending News

About SNY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SNY--
Sanofi